APA (7th ed.) Citation

Muraviev, Y. V., Gridneva, G. I., Muravieva, L. A., Muravieva, N. V., Alexeeva, A. V., Nurbaeva, K. S., . . . Rozov, A. V. (2018). Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis. IMA-PRESS LLC.

Chicago Style (17th ed.) Citation

Muraviev, Yu. V., G. I. Gridneva, L. A. Muravieva, N. V. Muravieva, A. V. Alexeeva, K. S. Nurbaeva, K. M. Mikhailov, and A. V. Rozov. Rationales for Discontinuation of Disease-modifying Antirheumatic Drugs, Biologic Agents, and Tofacitinib in Rheumatoid Arthritis. IMA-PRESS LLC, 2018.

MLA (9th ed.) Citation

Muraviev, Yu. V., et al. Rationales for Discontinuation of Disease-modifying Antirheumatic Drugs, Biologic Agents, and Tofacitinib in Rheumatoid Arthritis. IMA-PRESS LLC, 2018.